Worth reading
55In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
40
¥ million (improvement in operating results)Wording
Conditional
How definitive the wording is.Contents of this document
Financial results presentationFirst quarter of the fiscal year ending December 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥183 million+28.1%
Operating profit¥-458 million
Ordinary income¥-488 million
Net income¥-513 million
Full-year earnings forecast
Net Sales
¥720 million
Operating loss
¥2,028 million
Ordinary loss
¥2,053 million
Net loss for the period
¥2,090 million
Research and Development Expenses
¥1,950 million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Operating loss22.6
Research and Development Expenses22.4
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Within the expected range for the full-year planNew initiatives
- Issuance of stock acquisition rights to advance the clinical development of docirbrutinib
- Preparation for the start of a physician-initiated Phase 1b trial of a three-drug combination of monzosertib
- Preparation for clinical trials under the MOU with The University of Texas MD Anderson Cancer Center
Key KPIsA metric the company considers important as a management benchmark.
- Revenue from the drug discovery support business¥183 millionYear on year against the same period last year+28.1%
- Incidence of treatment-related Grade 3 or higher adverse events in the Phase 1b trial of docirbrutinib13 %
- Number of clinical trial sites13 Facility
Segment results
Drug discovery support
Net Sales
¥183 million+28.1%
Operating profit (loss)
¥19 million
yoy_change31
Drug Discovery
Operating profit (loss)
¥-478 million
yoy_change7
Financial targets
Equity ratio
Actual results-8.1 %
Market Size / Share
- Total sales of existing BTK inhibitors120 Over US$100 million
- AML treatment market size$38 100 million
- Chronic spontaneous urticaria market size22 Over US$100 million
| Item | Details |
|---|---|
| Document type | Financial results presentation |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | ¥183 million (YoY +28.1%) |
| Operating profit | ¥-458 million |
| Ordinary income | ¥-488 million |
| Net income | ¥-513 million |
| Full-year earnings forecast | Net Sales ¥720 million / Operating loss ¥2,028 million / Ordinary loss ¥2,053 million / Net loss for the period ¥2,090 million / Research and Development Expenses ¥1,950 million |
| Progress against full-year forecast | Operating loss 22.6 / Research and Development Expenses 22.4 |
| Self-assessment against the plan | Within the expected range for the full-year plan |
| Segment results | Drug discovery support Net Sales ¥183 million (YoY +28.1%) / Operating profit (loss) ¥19 million / Drug Discovery Net Sales Not disclosed / Operating profit (loss) ¥-478 million |
| Key KPIs | Indicator name Revenue from the drug discovery support business / Value ¥183 million / Year on year against the same period last year ¥28.1 million, Indicator name Incidence of treatment-related Grade 3 or higher adverse events in the Phase 1b trial of docirbrutinib / Value 13 % / Year on year against the same period last year Not disclosed, Indicator name Number of clinical trial sites / Value 13 Facility / Year on year against the same period last year Not disclosed |
| Financial targets | Equity ratio Actual results -8.1 % / Target Not disclosed |
| Market Size / Share | Subject Total sales of existing BTK inhibitors / Value 120 Over US$100 million, Subject AML treatment market size / Value $38 100 million, Subject Chronic spontaneous urticaria market size / Value 22 Over US$100 million |
| New initiatives | Issuance of stock acquisition rights to advance the clinical development of docirbrutinib, Preparation for the start of a physician-initiated Phase 1b trial of a three-drug combination of monzosertib, Preparation for clinical trials under the MOU with The University of Texas MD Anderson Cancer Center |
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelling, general and administrative expensesResults for the three months of the current quarterBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the drug discovery support business, protein sales to customers in Japan and China and contract testing services for customers in Japan and Europe remained firm. In the drug discovery business, research and development expenses increased as the Company continued to make proactive investments in development-stage programs, including docirbrutinib.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.